Prion inhibition
The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.
1. An isolated PrP binding antibody or antigen or antigen binding fragment thereof comprising a heavy chain variable domain sequence encoded by the nucleic acid sequence of SEQ ID NO: 1 and a light chain variable domain sequence encoded by the nucleic acid sequence of SEQ ID NO: 2.
2. An isolated PrP binding antibody or antigen or antigen binding fragment thereof comprising a heavy chain variable domain sequence encoded by the nucleic acid sequence of SEQ ID NO:3 and a light chain variable domain sequence encoded by the nucleic acid sequence of SEQ ID NO:4.
3. An isolated PrP binding antibody or antigen that contains the same V H CDRs 1, 2 and 3 as encoded by the nucleotide sequence of SEQ ID NO:1 and V L CDRs 1, 2, and 3 as encoded by the sequence of SEQ ID NO:2 or an antigen binding fragment of said antibody.
4. An isolated PrP binding antibody that contains the same V H CDRs 1, 2 and 3 as encoded by the nucleotide sequence of SEQ ID NO: 3 and V L CDRs 1, 2, and 3 as encoded by the sequence of SEQ ID NO: 4 or an antigen binding fragment of said antibody.
5. An isolated nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.
6. An isolated polypeptide encoded by nucleic acid selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.
7. A composition comprising an antibody of claim 1 .
8. A composition comprising an antibody of claim 2 .
9. A composition comprising an antibody of claim 3 .
10. A composition comprising an antibody of claim 4 .
11. A composition comprising nucleic acid of claim 5 .
12. A composition comprising a polypeptide of claim 6 .